CC亚族趋化因子配体20/CC型趋化因子受体6在肝癌及其他肿瘤中的作用

吴静; 孟庆华

doi:10.3969/j.issn.1001-5256.2018.06.042

CC亚族趋化因子配体20/CC型趋化因子受体6在肝癌及其他肿瘤中的作用

DOI: 10.3969/j.issn.1001-5256.2018.06.042

吴静,
孟庆华

首都医科大学附属北京佑安医院肝病重症医学科

基金项目:

国家自然科学基金资助项目(81470877)；首都卫生发展科研专项基金资助项目(2016-1-2181)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1373
- HTML全文浏览量: 21
- PDF下载量: 349
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-11
- 出版日期: 2018-06-20

Research advances in the role of CCL20/CCR6 in liver cancer and other tumors

Department of Severe Liver Disease, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 趋化因子/受体在炎症、组织损伤等病理生理活动中的作用已较为明确,近年来越来越多的研究集中其在肿瘤微环境中对肿瘤的影响。总结了近年来CC亚族趋化因子配体20(CCL20)及其受体CCR6在肝癌及其他肿瘤中的研究进展,分析其推动肿瘤进展的可能机制及其对肿瘤预后的影响。阻断CCL20/CCR6的相互作用,可能为肝癌的靶向治疗提供新的方向。
- 肝肿瘤 /
- 趋化因子CCL20 /
- 受体,CCR6 /
- 综述
Abstract: The role of chemokines/receptors in the pathophysiological activities such as inflammation and tissue injury has been clarified. In recent years, there have been increasing studies on their effect on tumors in the tumor microenvironment. This article reviews research advances in C-C motif chemokine ligand 20 (CCL20) and its receptor CCR6 in liver cancer and other tumors in recent years and analyzes the possible mechanism by which CCL20 and CCR6 promote tumor progression and their effect on tumor prognosis. Blocking CCL20/CCR6 interaction may provide a new direction for the targeted therapy for liver cancer.
- liver neoplasms /
- chemokine CCL20 /
- receptors, CCR6 /
- review

HTML全文

参考文献(40)

[1]DU D, LIU Y, QIAN H, et al.The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma[J].Int J Mol Sci, 2014, 15 (4) :6441-6452.

[2]YANG Y, YU MW, YANG GW, et al.Research progress of SDF-1/CXCR4 axis and tumor metastasis[J].China Med Herald, 2016, 13 (33) :34-38. (in Chinese) 杨永, 于明薇, 杨国旺, 等.SDF-1/CXCR4轴与肿瘤转移研究进展[J].中国医药导报, 2016, 13 (33) :34-38.

[3]ARYA M, PATEL HR, WILLIAMSON M.Chemokines:Key players in cancer[J].Curr Med Res Opin, 2003, 19 (6) :557-564.

[4]BALKWILL F.Cancer and the chemokine network[J].Nat Rev Cancer, 2004, 4 (7) :540-550.

[5]NELSON RT, BOYD J, GLADUE RP, et al.Genomic organization of the CC chemokine mip-3alpha/CCL20/larc/exodus/SCYA20, showing gene structure, splice variants, and chromosome localization[J].Genomics, 2001, 73 (1) :28-37.

[6]SCHUTYSER ES, STRUYF S, van DAMME J.The CC chemokine CCL20 and its receptor CCR6[J].Cytokine Growth Factor Rev, 2003, 14 (5) :409-426.

[7]YAMAUCHI K, AKBAR SM, HORIIKE N, et al.Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma:Relationship with clinical factors and prognostic importance during therapy[J].Int J Mol Med, 2003, 11 (5) :601-605.

[8]KUCHARZIK T, HUDSON III J, WAIKEL R, et al.CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets:Demonstration using a CCR6 EGFP knock-in mouse[J].Eur J Immunol, 2002, 32 (1) :104-112.

[9]HIESHIMA K, IMAI T, OPDENAKKER G, et al.Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver.Chemotactic activity for lymphocytes and gene localization on chromosome 2[J].J Biol Chem, 1997, 272 (9) :5846-5853.

[10]SCHMUTH M, NEYER S, RAINER C, et al.Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function[J].Exp Dermatol, 2002, 11 (2) :135-142.

[11]LUKACS NW, PROSSER DM, MARIA W, et al.Requirement for the chemokine receptor ccr6 in allergic pulmonary inflammation[J].J Exp Med, 2001, 194 (4) :551-555.

[12]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, andtreatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[13]HAN MS, MOON KS, LEE KH, et al.Brain metastasis from hepatocellular carcinoma:The role of surgery as a prognostic factor[J].BMC Cancer, 2013, 13:567.

[14]LIOTTA LA.An attractive force in metastasis[J].Nature, 2001, 410 (6824) :24-25.

[15]CARR BI, GUERRA V.HCC and its microenvironment[J].Hepatogastroenterology, 2013, 60 (126) :1433-1437.

[16]LEONARDI GC, CANDIDO S, CERVELLO M, et al.The tumor microenvironment in hepatocellular carcinoma (review) [J].Int J Oncol, 2012, 40 (6) :1733-1747.

[17]SAKON M, NAGANO H, DONO K, et al.Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy:Analysis based on tumor hemodynamics[J].Arch Surg, 2002, 137 (1) :94-99.

[18]DING XJ.Diagnostic and prognostic value of CCL20 in patients with hepatocellular carcinoma[D].Jinan:Shandong Univ, 2012. (in Chinese) 丁祥就.趋化因子CCL20对肝癌诊断和预后的价值研究[D].济南:山东大学, 2012.

[19]CHANG XL.Relationship between CCR6/CCL20/Th17 axis and vascular invasion and metastasis of hepatocellular carcinoma[D].Guangzhou:Guangzhou Med Univ, 2014. (in Chinese) 畅秀丽.CCL20/CCR6/Th17轴与肝细胞癌血管浸润转移关系探讨[D].广州:广州医科大学, 2014.

[20]HE H, WU J, ZANG M, et al.CCR6 (+) B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis[J].Am J Cancer Res, 2017, 7 (5) :1151-1163.

[21]LI WM, LIU HR.CCL20-CCR6 cytokine network facilitate treg activity in advanced grades and metastatic variants of hepatocellular carcinoma[J].Scand J Immunol, 2016, 83 (1) :33-37.

[22]UCHIDA H, IWASHITA Y, SASAKI A, et al.Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2006, 21 (1 Pt 1) :161-168.

[23] LU E, SU J, ZHOU Y, et al.CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway[J].Biomed Pharmacother, 2017, 85:486-492.

[24]HAN G, WU D, YANG Y, et al.Crk L meditates CCL20/CCR6-induced EMT in gastric cancer[J].Cytokine, 2015, 76 (2) :163-169.

[25]KAPUR N, MIR H, CLARK LII CE, et al.CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition[J].Br J Cancer, 2016, 114 (12) :1343-1351.

[26]GHADJAR P, LODDENKEMPER C, COUPLAND SE, et al.Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer[J].J Cancer Res Clin Oncol, 2008, 134 (11) :1181-1189.

[27]LIU BY, JIAYP, MA J, et al.Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer[J].ABBS, 2016, 48 (12) :1067-1074.

[28]ABIKO Y, NISHIMURA M, KASANO K, et al.Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma[J].Arch Oral Biol, 2003, 48 (2) :171-175.

[29]IKEDA S, KITADATE A, ITO M, et al.Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma[J].Oncotarget, 2016, 7 (12) :13563-13574.

[30]LI J, WANG FY, GUO SP.Expression and clinical significance of chemokine CCL20 and its receptor CCR6 in esophageal squamous carcinoma tissues[J].Chin Remed Clin, 2014, 14 (6) :748-749. (in Chinese) 李嘉, 王飞云, 郭石平.CCL20及其受体CCR6在食管鳞癌组织中的表达及意义[J].中国药物与临床, 2014, 14 (6) :748-749.

[31]ZENG W, CHANG H, MA M, et al.CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production[J].Exp Mol Pathol, 2014, 97 (1) :184-190.

[32]ZHANG X, HU Z, MENG A, et al.Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma[J].Oncology Letters, 2017, 14 (6) :8183-8189.

[33]BRAND S, OLSZAK T, BEIGEL F, et al.Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells[J].J Cell Biochem, 2006, 97 (4) :709-723.

[34]DELLACASAGRANDE J, SCHREURS OJF, HOFGAARD PO, et al.Liver metastasis of cancer facilitated by chemokine receptor CCR6[J].Scand J Immunol, 2003, 57 (6) :534-544.

[35]FUJII H, ITOH YK, YAMAUCHI N, et al.Chemokine CCL20 enhances the growth of Hu H7 cells via phosphorylation of p44/42MAPK in vitro[J].Biochem Biophys Res Commun, 2004, 322 (3) :1052-1058.

[36]LU E, SU J, ZHOU Y, et al.CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway[J].Biomed Pharmacother, 2017, 85:486-492.

[37]MARSIGLIANTE S, VETRUGNO C, MUSCELLA A.CCL20 induces migration and proliferation on breast epithelial cells[J].J Cell Physiol, 2013, 228 (9) :1873-1883.

[38]YE LY, CHEN W, BAI XL, et al.Hypoxia-induced epithelial-tomesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis[J].Cancer Res, 2016, 76 (4) :818-830.

[39]HOU KZ, FU ZQ, GONG H.Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition[J].World J Gastroenterol, 2015, 21 (2) :475-483.

[40]QIU W, WANG G, SUN X, et al.The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma[J].Med Oncol, 2015, 32 (3) :75.

施引文献

资源附件(0)

访问统计